ANGO earnings analysis
What we found in ANGO's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
AngioDynamics, Inc. reported a 9.5% increase in revenue to $320.2 million for the fiscal year ending May 31, 2026, driven by an 18.4% growth in its Med Tech segment, particularly from its Auryon and NanoKnife products. However, the company also experienced a net loss of $36.7 million compared to $34 million the previous year, reflecting ongoing challenges in operational costs and legal expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Total revenue increased by 9.5% to $320.2 million in FY2026 from $292.5 million in FY2025.
- Med Tech Segment Success
- The Med Tech segment grew by 18.4%, contributing $149.9 million in FY2026.
- Gross Margin Improvement
- Gross margin increased by 70 basis points to 54.6% in FY2026, reflecting better cost management.
- Positive Free Cash Flow
- Cash flow from operations improved significantly, reaching $3.1 million for FY2026 compared to a usage of $10.1 million in FY2025.
- Cost Savings from Restructuring Plan
- The ongoing restructuring plan is expected to yield $15 million in annual savings starting in FY2027.
- Strong International Sales
- International sales increased 8.5% year-over-year, contributing $45.3 million in FY2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Net Loss
- Net loss increased to $36.7 million in FY2026 from $34.0 million in FY2025, reflecting rising operational costs.
- Litigation Costs
- Legal expenses increased significantly, contributing to net losses; ongoing lawsuits pose a financial risk.
- Cybersecurity Risks
- A cyber-attack could expose the company to significant operational and financial impacts, with a reported emphasis on enhancing cybersecurity measures.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.88
- Gross margin
- 54.6%
- Segment
- Med Tech
- Segment
- Med Device
What they said about what is next.
Annual outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-Q · April 2, 2026
- AngioDynamics reported Q3 net sales of $78,423,000 (up $6,419,000 vs. $72,004,000 a year ago) but posted a wider net loss of $(8,084,000) compared with $(4,407,000) in the prior-year quarter, driving diluted loss per…
- 10-Q · January 6, 2026
- AngioDynamics reported Q2 net sales of $79,433,000, up $6,588,000 (9.0%) versus prior-year quarter, with gross margin expanding to 56.4% from 54.8% and operating loss narrowing to $(6,125,000) from $(11,094,000).…
- 10-Q · October 2, 2025
- AngioDynamics reported quarterly net sales of $75,711,000 (up $8,220,000 or ~12.2% vs. $67,491,000 a year ago) with gross margin improving to 55.3% and operating loss narrowing to $(10,656,000) from $(13,098,000).…
- 10-K · July 18, 2025
- AngioDynamics positions itself as a diversified med‑tech company pursuing growth through R&D, regulatory pathway expansion and customer‑centric sales execution, with two reporting segments (Med Tech and Med Device).…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ANGO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever